Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
Key Points
Ultra-hypofractionated radiotherapy shows comparable results to conventionally fractionated approaches over ten years.
The primary outcome measure indicates non-inferiority in treatment effectiveness between the two radiotherapy methods.
This randomized phase 3 trial involved multiple treatment centers assessing patient outcomes in prostate cancer.
Highlights the importance of optimizing radiotherapy techniques for localized prostate cancer, with implications for patient care.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial | Synapse